March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection.

The company said the drug, Arikayce, did not reduce bacterial density, a measure of change in infection, in patients with nontuberculous mycobacterial lung infections.

The trial compared the drug, in combination with a standard treatment, to a combination of placebo and the standard treatment.

(Reporting By Vrinda Manocha in Bangalore; Editing by Savio D'Souza)